https://www.selleckchem.com/pr....oducts/tegatrabetan.
COVID-19 characterized by refractory hypoxemia increases patient mortality because of immunosuppression effects. This study aimed to evaluate the efficacy of immunomodulatory with thymosin α1 for critical COVID-19 patients. This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec. 2019 to Mar. 2020. Thymosin α1 was administrated with 1.6mg qd or q12 h for 5days. The primary outcomes were the 28-day and 60-day mortality, the secondary outcomes
Like
Comment
Share
